Janus Kinase (JAK) Inhibitors

Janus kinase (JAK) inhibitors are a therapeutic class of targeted small-molecule medications that disrupt intracellular cytokine signaling pathways In addition, specific JAK inhibitors are indicated for dermatologic disorders such as atopic dermatitis, vitiligo, and alopecia areata, as well as hematologic malignancies, including myelofibrosis and polycythemia vera

Janus kinase (JAK) inhibitors are a therapeutic class of targeted small-molecule medications that disrupt intracellular cytokine signaling pathways

By inhibiting one or more members of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, and TYK2), these agents downregulate the downstream phosphorylation and activation of signal transducers and activators of transcription, thereby suppressing pro-inflammatory cytokine production and abnormal cellular proliferation

By inhibiting one or more members of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, and TYK2), these agents downregulate the downstream phosphorylation and activation of signal transducers and activators of transcription, thereby suppressing pro-inflammatory cytokine production and abnormal cellular proliferation

Therapeutics in this class are widely utilized across rheumatology and gastroenterology for autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis In addition, specific JAK inhibitors are indicated for dermatologic disorders such as atopic dermatitis, vitiligo, and alopecia areata, as well as hematologic malignancies, including myelofibrosis and polycythemia vera

In addition, specific JAK inhibitors are indicated for dermatologic disorders such as atopic dermatitis, vitiligo, and alopecia areata, as well as hematologic malignancies, including myelofibrosis and polycythemia vera